Last updated: February 6, 2026
What is the case about?
Mallinckrodt IP Unlimited Company filed a patent infringement lawsuit against Aurobindo Pharma USA, Inc. in the U.S. District Court for the District of Delaware. The case concerns the alleged infringement of U.S. Patent No. 9,703,808, related to formulations of hydrocodone bitartrate and APIs used in opioid medications.
When was the case filed and what is the procedural posture?
The complaint was filed on December 21, 2017. Aurobindo initially moved to dismiss in September 2018, which was denied. The case has since engaged in claim construction, discovery, and dispositive motions. As of 2023, the case remains active, with significant developments in infringement and validity issues.
What are the key patent rights involved?
The patent at stake, U.S. Patent No. 9,703,808, claims methods of manufacturing pharmaceutical compositions with specific properties that improve stability and bioavailability. It is set to expire in 2034. The patent’s claims cover specific hydrocodone formulations and processes intended to reduce abuse potential.
What are the allegations and defenses?
Mallinckrodt alleges that Aurobindo manufactures and sells generic opioid products infringing the patent’s claims in the U.S. market. Aurobindo contends that the patent is invalid due to obviousness, lack of novelty, or inadequate disclosure, and denies infringement.
What were the key rulings?
-
Claim Construction: The court adopted a nuanced interpretation of certain claim terms, emphasizing the importance of language relating to the chemical composition and manufacturing process.
-
Motion to Dismiss: Aurobindo’s motion to dismiss for failure to state patent infringement was denied, allowing the case to proceed to discovery.
-
Summary Judgment Claims: Both parties have filed motions for summary judgment on issues of validity and infringement. As of 2023, these motions are pending decision.
What are the major issues in dispute?
-
Validity of the patent: Aurobindo challenges the patent’s novelty and non-obviousness under 35 U.S.C. §§ 102, 103. Key prior art references include earlier pharmaceutical formulations and manufacturing methods.
-
Infringement: Whether Aurobindo’s generic formulations and processes infringe the patent claims. The analysis hinges on claim interpretation and technical data regarding the formulations.
-
Damages and Injunctive Relief: The case seeks injunctive relief and monetary damages for the alleged infringement. Actual damages are sought based on lost market share and royalty rates.
Recent developments
In February 2022, the court denied motions for summary judgment regarding validity and infringement, citing unresolved disputes over claim scope and prior art issues. The case waits for trial scheduling. Expert disclosures are ongoing, with disputes centered on technical and patent law issues.
Strategic considerations for stakeholders
-
Patent validity: Aurobindo’s success depends on establishing invalidity, especially via obviousness challenges based on prior art.
-
Infringement: Mallinckrodt must demonstrate Aurobindo’s products meet all claim limitations, particularly the specific formulation and manufacturing process.
-
Market implications: A ruling favoring Mallinckrodt could result in injunctive relief or market entry restrictions on Aurobindo’s generic opioid products.
-
Duration and cost: The case, initiated in 2017, faces slow progress, with a potential trial year in 2024 or later, indicating long-term litigation risks.
Key Takeaways
- The case exemplifies typical patent infringement disputes in the pharmaceutical sector, particularly generics challenging branded patents.
- Claim construction plays a pivotal role in determining infringement and validity.
- Success hinges on the ability to establish the patent’s novelty and non-obviousness amid complex prior art references.
- Longer litigation timelines reflect procedural complexity and technical disputes.
- Outcomes could influence market entry strategies for opioid generics.
FAQs
1. What limited the patent’s scope in the case?
Claim interpretation, especially of manufacturing process terms, narrowed the patent’s scope, affecting infringement and validity prospects.
2. How does prior art influence the validity challenge?
Prior art, including earlier formulations and manufacturing techniques, serves as the basis for obviousness and novelty disputes, critical in validity defenses.
3. What legal strategies does Mallinckrodt likely pursue?
Focusing on detailed claim construction to assert infringement and countering validity challenges with technical evidence demonstrating patent novelty.
4. How might this case impact the opioid market?
A ruling favoring Mallinckrodt could prevent Aurobindo’s generic entry, impacting pricing and availability of certain formulations.
5. When might outcomes be expected?
A trial date is likely in 2024 or later, with dispositive motions ongoing and appellate routes possible post-trial.
References
[1] Court docket: Mallinckrodt IP Unlimited Company v. Aurobindo Pharma USA, Inc., 1:17-cv-01877, U.S. District Court for the District of Delaware.
[2] Patent: U.S. Patent No. 9,703,808.
[3] Court decisions and filings available on PACER and court public records.
